NCT06785506Active, not recruiting
Multiple-biomarker Approach for Individualized Treatment of Heart Failure With Preserved Ejection Fraction
A Dynamic, Multiple-biomarker Approach Aiming for Individualized Treatment of Heart Failure With Preserved Ejection Fraction (ADAPT-HFpEF)
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
The primary objective is to investigate the association between temporal evolutions of blood biomarkers and clinical adverse events, in order to produce a dynamic, individual, and accurate prediction model for patients with HFpEF. Moreover several secondary objectives will be investigated.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 15 Jul 2024
- Start date
- 25 Nov 2022
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- Erasmus Medical Center
- Diseases
- Heart failure
- NCT number
- NCT06785506
What you commit to
- Study type: Observational
- Planned participants: 200
- From 25 Nov 2022 to the primary completion date, 1 Nov 2026
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Scheduled for surgery or intervention for both coronary and non-coronary indication within 6 months of inclusion
Other illness
- Congenital heart disease
- Coexistent condition with life expectancy of \<1 year
Lab values
- History of LVEF ≤40%
- Impaired renal function, defined as eGFR \< 20 mL/min/1.73 m2 (CKD-EPI) or requiring dialysis at the time of screening
- Acute or chronic liver disease, defined by serum levels of transaminases or alkaline phosphatase more than three times the upper limit of normal at screening
Other
- COPD Gold stage IV
- Pregnancy
- Unlikely to appear at all scheduled follow-up visits
- Linguistic barrier
Who the study is looking for
- Age of 18 years or older
- Capable of understanding and signing informed consent
- A diagnosis of HFpEF according to the HFA-PEFF diagnostic algorithm of the ESC or/and a high (90%) probability of HFpEF according to the H2FPEF score, i.e. a score of 6 or higher.
Age in the registry: 18 years to - · Sex: All
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Noordwest Ziekenhuisgroep Coordinator of this site? Confirm its status | Alkmaar | Netherlands | Unknown status |
| Amsterdam UMC Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Unknown status |
| OLVG Ziekenhuis Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Unknown status |
| Erasmus MC Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Unknown status |
| Ikazia Ziekenhuis Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Unknown status |
| Franciscus Gasthuis & Vlietland Ziekenhuis Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.